AMTB vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AMTB exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating stable but not strong fundamentals. The absence of an Altman Z-Score prevents a full distress risk assessment, though the Price/Book of 0.93 suggests the stock trades below tangible book value. Strong revenue growth of 576.5% YoY and a low forward P/E of 7.88 signal potential value, but weak ROA of 0.64% and inconsistent earnings surprises temper optimism. Analysts recommend a 'buy' with a $22.75 target, implying modest upside from current levels.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
AMTB vs JPM: Head-to-Head Comparison
This page compares Amerant Bancorp Inc. (AMTB) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.